Contrast Ultrasound Imaging for Identification of Early Responder Tumor Models to Anti-Angiogenic Therapy

Ultrasound in Medicine and Biology, 04/09/2012

The authors conclude that the response to bevacizumab (BV) can be identified soon after initiation of treatment, often within 3 days, by use of contrast–enhanced ultrasound imaging (CEUS) molecular imaging techniques. The use of a noninvasive ultrasound approach may allow for earlier and more effective determination of efficacy of antiangiogenic therapy.

Print Article Summary Cat 2 CME Report